| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Ferutinin targets the mitochondrial membrane by acting as an electrogenic Ca2+-ionophore to increase calcium permeability. It also targets estrogen receptors, acting as an ERalpha agonist (IC50=33.1 nM) and an ERbeta agonist/antagonist (IC50=180.5 nM).
|
|---|---|
| ln Vitro |
Ferutinin has the ability to cause apoptosis in a range of cell types, including estrogen-dependent cancer cells MCF-7, leukemic T cell lines (Jurkat), colon cancer cells from humans and mice (Caco-2, CT26, HT29), and cancer cells from the bladder (TCC). Ferutinin is suggested as an anti-osteoporotic phytoestrogen because it promotes bone mineralization [2]. Ferutinin induces apoptosis in several cell lines in a manner that is dependent on the mitochondria and dramatically increases the permeability of artificial and cell membranes to Ca2+ ions. Additionally, membrane potential is dose-dependently dissipated by ferunitinin alone (10–60 µM). When Ca2+ ions are present, ferunitin (10–60 µM) significantly depolarizes the inner mitochondrial membrane [2].
Ferutinin manifests antiproliferative activity, inducing apoptosis in various cell types including MCF-7 cancer cells, Jurkat T-cells, and colon carcinoma cells. It dissipates mitochondrial membrane potential dose-dependently and induces apoptosis in a mitochondria-dependent manner. |
| ln Vivo |
Ferutinin potentiates bone mineralization and is proposed as an anti-osteoporosis phytoestrogen in research models. It produces apoptotic cell death in different cell lines and considerably increases the permeability of cellular membranes to Ca2+ ions.
|
| Enzyme Assay |
Binding affinity and functional activity at estrogen receptors (ERalpha and ERbeta) are measured using competitive binding assays with radiolabeled estradiol. Ionophore activity is assessed by measuring Ca2+ flux across artificial lipid bilayers or isolated mitochondria using fluorescent calcium indicators.
|
| Cell Assay |
Cell viability is assessed via MTT assays across a concentration range. Apoptosis is confirmed through Annexin V/PI staining and caspase activity measurements. Mitochondrial membrane potential is measured using fluorescent probes such as JC-1 or TMRM.
|
| Animal Protocol |
Dedicated in vivo animal models include ovariectomized rodents for osteoporosis research to assess bone mineral density. Xenograft tumor models in mice are used to evaluate antitumor efficacy via tumor volume measurement and apoptosis analysis.
|
| ADME/Pharmacokinetics |
Standard PK profiling is not extensively published. Based on its lipophilic terpenoid nature, Ferutinin is expected to have good membrane permeability, but detailed PK parameters such as half-life, bioavailability, and tissue distribution require further investigation.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for Ferutinin is limited. As a natural terpenoid, comprehensive acute and chronic toxicity studies have not been widely reported. Researchers should handle it with standard laboratory precautions.
|
| References |
|
| Additional Infomation |
Ferutinin is an organic molecular entity. It has been reported that Ferutinine is present in Ferula jaeschkeana, Ferula akitschkensis, and other organisms with available data.
Ferutinin is a phytoestrogen with higher binding affinity for ERalpha than ERbeta and demonstrates tissue-selective estrogenic effects. Its calcium ionophore activity distinguishes it from classical ER ligands, representing a dual mechanism for its antiproliferative and bone-protective effects. |
| Molecular Formula |
C22H30O4
|
|---|---|
| Molecular Weight |
358.471207141876
|
| Exact Mass |
358.214
|
| CAS # |
41743-44-6
|
| PubChem CID |
354654
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
489.0±45.0 °C at 760 mmHg
|
| Flash Point |
164.4±22.2 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.573
|
| LogP |
5.72
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
26
|
| Complexity |
561
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC1=CC[C@]2(CC[C@]([C@@H]2[C@H](C1)OC(=O)C3=CC=C(C=C3)O)(C(C)C)O)C
|
| InChi Key |
CYSHNJQMYORNJI-YUVXSKOASA-N
|
| InChi Code |
InChI=1S/C22H30O4/c1-14(2)22(25)12-11-21(4)10-9-15(3)13-18(19(21)22)26-20(24)16-5-7-17(23)8-6-16/h5-9,14,18-19,23,25H,10-13H2,1-4H3/t18-,19+,21-,22+/m0/s1
|
| Chemical Name |
[(3R,3aS,4S,8aR)-3-hydroxy-6,8a-dimethyl-3-propan-2-yl-1,2,3a,4,5,8-hexahydroazulen-4-yl] 4-hydroxybenzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7896 mL | 13.9482 mL | 27.8963 mL | |
| 5 mM | 0.5579 mL | 2.7896 mL | 5.5793 mL | |
| 10 mM | 0.2790 mL | 1.3948 mL | 2.7896 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
